{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:42:14Z","timestamp":1790192534488,"version":"4.1.0"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.clinbiochem.2019.03.002","type":"journal-article","created":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T12:24:04Z","timestamp":1551961444000},"page":"1-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["FGF23: Clinical usefulness and analytical evolution"],"prefix":"10.1016","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6656-7227","authenticated-orcid":false,"given":"Charlotte","family":"Fauconnier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00eblle","family":"Gillerot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clotilde","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Catherine","family":"Pouleur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Gruson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0005","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev-physiol-030212-183727","article-title":"Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism","volume":"75","author":"Hu","year":"2013","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0010","first-page":"391","article-title":"Fibroblast growth factor 23 \u2013 structure, Function and Role in Kidney Diseases","volume":"21","author":"Kocelak","year":"2012","journal-title":"Adv. Clin. Exp. Med."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0015","doi-asserted-by":"crossref","first-page":"6120","DOI":"10.1074\/jbc.C500457200","article-title":"Regulation of fibroblast growth factor-23 signaling by Klotho","volume":"281","author":"Kurosu","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0020","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3389\/fendo.2018.00278","article-title":"Paracrine effects of FGF23 on the heart","volume":"9","author":"Leifheit-Nestler","year":"2018","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0025","doi-asserted-by":"crossref","first-page":"5945","DOI":"10.1073\/pnas.111154898","article-title":"FGF23, hypophosphatemia, and rickets: has phosphatonin been found?","volume":"98","author":"Strewler","year":"2002","journal-title":"PNAS"},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0030","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00774-005-0625-4","article-title":"Comparison of two assays for fibroblast growth factor (FGF)-23","volume":"23","author":"Ito","year":"2005","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0035","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1152\/physrev.00002.2011","article-title":"Regulation and function of the FGF23\/Klotho endocrine pathways","volume":"92","author":"Martin","year":"2012","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0040","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1177\/0004563213510708","article-title":"Fibroblast growth factor 23","volume":"51","author":"Smith","year":"2014","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0045","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.tem.2009.02.001","article-title":"Bone as an endocrine organ","volume":"20","author":"Fukumoto","year":"2009","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0050","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.bone.2008.02.014","article-title":"Clinical usefulness of measurement of FGF23 in hypophosphatemic patients. Proposal of diagnostic criteria using FGF23 measurement","volume":"42","author":"Endo","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0055","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1210\/jc.2002-021105","article-title":"Increased circulatory level of biologically active full-length FGF23 in patients with hypophosphatemic rickets\/osteomalacia","volume":"87","author":"Yamazaki","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0060","article-title":"Assessment of Fibroblast growth factor 23 as an early predictor in chronic kidney disease patients","volume":"3","author":"Abd ELfattah","year":"2018","journal-title":"IJRD"},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0065","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","article-title":"Chronic kidney disease","volume":"389","author":"Webster","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0070","article-title":"Fibroblast growth factor 21 in chronic kidney disease","author":"Anuwatmatee","year":"2017","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0075","doi-asserted-by":"crossref","first-page":"57","DOI":"10.5527\/wjn.v4.i1.57","article-title":"Biomarkers in chronic kidney disease, from kidney function to kidney damage","volume":"4","author":"Lopez-Giacoman","year":"2015","journal-title":"World J. Nephrol."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0080","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1046\/j.1523-1755.2003.00328.x","article-title":"Circulating concentration of FGF23 increases as renal function declines in patient with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers","volume":"64","author":"Larsson","year":"2003","journal-title":"Kidney Int."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0085","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/ki.2012.176","article-title":"Update on fibroblast growth factor 23 in chronic kidney disease","volume":"82","author":"Wolf","year":"2012","journal-title":"Kidney Int."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0090","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/ki.2011.47","article-title":"Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease","volume":"79","author":"Isakova","year":"2011","journal-title":"Kidney Int."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0095","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/ki.2010.313","article-title":"Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease","volume":"78","author":"Hasegawa","year":"2010","journal-title":"Kidney Int."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0100","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.clinbiochem.2011.01.009","article-title":"Impaired GFR is the most important determinant for FGF-23 increase in chronic kidney disease","volume":"44","author":"Filler","year":"2011","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0105","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1210\/jc.2012-1811","article-title":"Biological variability of plasma intact and C-term FGF23 measurement","volume":"97","author":"Smith","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0110","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1359\/jbmr.060507","article-title":"Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women","volume":"21","author":"Burnett","year":"2006","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0115","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1210\/jc.2008-0326","article-title":"Relationship between plasma fibroblast growth Factor-23 concentration and bone mineralization in children with renal failure on peritoneal Dialysis","volume":"94","author":"Wesseling-Perry","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0120","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1210\/jc.2009-1576","article-title":"The influence of glomerular filtration rate and age on fibroblast growth factor 23 serum levels in Pediatric chronic kidney disease","volume":"95","author":"Bacchetta","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0125","doi-asserted-by":"crossref","unstructured":"Marie Courbebaisse and Beate Lanske, Biology of fibroblast growth factor 23: from physiology to pathology, Cold Spring Harb. Perspect. Med. doi: https:\/\/doi.org\/10.1101\/cshperspect.a031260.","DOI":"10.1101\/cshperspect.a031260"},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0130","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.clinbiochem.2014.12.027","article-title":"Plasma fibroblast growth factor 23 concentration and iron status. Does the relationship exist in the elderly population?","volume":"48","author":"Bozentowicz-Wikarek","year":"2015","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bone.2017.02.005","article-title":"Low serum iron is associated with high serum intact FGF23 in elderly men","volume":"98","author":"Lewerin","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0140","doi-asserted-by":"crossref","first-page":"845","DOI":"10.5114\/aoms.2016.58647","article-title":"Fibroblast growth factor 23, iron and inflammation \u2013 are they related in early stages of chronic kidney disease?","volume":"4","author":"Lukaszyk","year":"2017","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0145","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000487368","article-title":"Inflammation and FGF23 in non-Dialysis patients with chronic kidney disease stages 3-5","volume":"43","author":"Muras-Szwedziaka","year":"2018","journal-title":"Kidney Blood Press. Res."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0150","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1002\/jbmr.1923","article-title":"effects of Iron deficiency Anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women","volume":"8","author":"Wolf","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0155","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.kint.2016.10.021","article-title":"Inflammation and elevated levels of FGF23 are independent risk factors of death in CKD","volume":"91","author":"Mendoza","year":"2017","journal-title":"Kidney Int."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0160","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1093\/ndt\/gfu063","article-title":"Fibroblast growth factor 23 (FGF23) and early chronic kidney disease in the elderly","volume":"29","author":"Chudek","year":"2014","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0165","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMoa0706130","article-title":"Fibroblast growth factor 23 and mortality among patients undergoing Hemodialysis","volume":"359","author":"Orlando","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0170","doi-asserted-by":"crossref","first-page":"57","DOI":"10.5527\/wjn.v4.i1.57","article-title":"Biomarkers in chronic kidney disease, from kidney function to kidney damage","volume":"4","author":"Lopez-Giacoman","year":"2015","journal-title":"World J. Nephrol."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0175","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.kint.2016.10.021","article-title":"Inflammation and elevated levels of FGF23 are independent risk factors of death in CKD","volume":"91","author":"Mendoza","year":"2017","journal-title":"Kidney Int."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0180","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000454959","article-title":"Fibroblast growth factor 23 predicts all-cause mortality in a dose-response fashion in pre-dialysis patients with chronic kidney disease","volume":"45","author":"Cheng","year":"2017","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0185","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000454961","article-title":"Is fibroblast growth factor 23 the new biomarker for cardiovascular mortality in chronic kidney disease patients?","volume":"45","author":"Filler","year":"2017","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0190","doi-asserted-by":"crossref","DOI":"10.2215\/CJN.04260415","article-title":"Anderson chronic renal insufficiency cohort study (CRIC): overview and summary of selected findings","volume":"10","author":"Denker","year":"2015","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0195","doi-asserted-by":"crossref","DOI":"10.2215\/CJN.04260415","article-title":"Anderson chronic renal insufficiency cohort study (CRIC): overview and summary of selected findings","volume":"10","author":"Denker","year":"2015","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0200","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1159\/000443452","article-title":"C-terminal to intact fibroblast growth factor 23 ratio in relation to estimated glomerular filtration rate in elderly population","volume":"41","author":"Bo\u017centowicz-Wikareka","year":"2016","journal-title":"Kidney Blood Press. Res."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0205","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1681\/ASN.2014121253","article-title":"Renal clearance of mineral metabolism biomarkers","volume":"27","author":"van Ballegooijen","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0210","doi-asserted-by":"crossref","unstructured":"Johanna Schauerte, Insa Emrich, Sarah Seiler-Mu\u00dfler et al, Cterminal FGF23 versus intact FGF23 as cardiovascular predictor in chronic kidney disease, Nephrol. Dial. Transplant. doi:https:\/\/doi.org\/10.1093\/ndt\/gfx123.","DOI":"10.1093\/ndt\/gfx123"},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0215","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1681\/ASN.2009121293","article-title":"Forging forward with 10 burning questions on FGF23 in kidney disease","volume":"21","author":"Wolf","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0220","doi-asserted-by":"crossref","unstructured":"Sharon M. Moe, Glenn M. Chertow, Patrick S. Parfrey et al, Cinacalcet, FGF23 and cardiovascular disease in hemodialysis: EVOLVE Trial DOI: https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.013876","DOI":"10.1161\/CIRCULATIONAHA.114.013876"},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0225","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002341","article-title":"Fibroblast growth factor 23 is an independent and specific predictor of mortality in patients with heart failure and reduced ejection fraction","author":"Koller","year":"2015","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0230","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/MAJ.0b013e3181815498","article-title":"Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients","volume":"337","author":"Hsu","year":"2009","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0235","first-page":"19","article-title":"Fibroblast growth factor-23 : a novel biomarker for cardiovascular disease in chronic kidney disease patients","volume":"38","author":"Papagianni","year":"2017","journal-title":"Sec. Med. Sci."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0240","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ijcard.2015.04.074","article-title":"Comparison of FGF23, ST2, Galectin-3 for prognostication of CV death in HF patients","volume":"189","author":"Gruson","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0245","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-02068-6","article-title":"FGF23\/FGFR4-mediated leftventricular hypertrophy is reversible","volume":"7","author":"Grabner","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0250","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/ndt\/gfv421","article-title":"Induction of cardiac FGF23\/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease","volume":"31","author":"Leifheit-Nestler","year":"2016","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0255","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0260","doi-asserted-by":"crossref","DOI":"10.1002\/emmm.201303716","article-title":"FGF23 regulates renal sodium handling and blood pressure","author":"Andrukhova","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0265","doi-asserted-by":"crossref","first-page":"64649","DOI":"10.18632\/oncotarget.11623","article-title":"FGF23 promotes myocardial fibrosis in mice through activation of \u03b2-catenin","volume":"7","author":"Hao","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0270","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/nrneph.2014.49","article-title":"Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease","volume":"10","author":"Scialla","year":"2014","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0275","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ijcard.2017.10.010","article-title":"Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure","volume":"253","author":"Ter Maaten","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0280","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.bone.2016.10.001","article-title":"Cardiac actions of FGF23","volume":"100","author":"Faul","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0285","first-page":"e1","article-title":"FGF23, its correlates and risk of MI \u2013 results from the EPIC-Germany case cohort study","volume":"241","author":"di Guiseppe","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0290","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1253\/circj.CJ-17-0826","article-title":"Changes in serum fibroblast growth factor 23 in patients with acute myocardial infarction","volume":"82","author":"Takahashi","year":"2018","journal-title":"Circ. J."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0295","first-page":"1","article-title":"Fibroblast growth factor 23 as novel biomarker for early risk stratification after ST-elevation myocardial infarction","volume":"0","author":"Reindl","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0300","doi-asserted-by":"crossref","first-page":"A1","DOI":"10.1136\/heartjnl-2016-309890.193","article-title":"Lack of fibroblast growth factor-23 (FGF23) preserves cardiac function in a murine model of acute myocardial infarction","volume":"102","author":"Ford","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0305","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.clinbiochem.2017.10.015","article-title":"Fibroblast growth factor 23 in patients with acute dyspnea: data from the Akershus Cardiac Examination (ACE) 2 Study","volume":"52","author":"Lyngbakken","year":"2018","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0310","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.clinbiochem.2018.09.003","article-title":"Incremental value of intact fibroblast growth factor 23 to natriuretic peptides for long-term risk estimation of heart failure patients","volume":"61","author":"Gruson","year":"2018","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0315","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/eci.12349","article-title":"FGF23 is associated with disease severity and prognosis in chronic heart failure","volume":"44","author":"Poelzl","year":"2014","journal-title":"Eur. J. Clin. Investig."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0320","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ijcard.2017.06.129","article-title":"Head to head comparison of intact and C-terminal fibroblast growth factor 23 in heart failure patients with reduced ejection fraction","volume":"248","author":"Gruson","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0325","article-title":"Usefulness of fibroblast growth factor 23 and soluble suppression of tumorigenicity 2 as predictors of poor outcome in heart failure with preserved ejection fraction","volume":"39","author":"Roy","year":"2018","journal-title":"Eur. Heart J."},{"issue":"224","key":"10.1016\/j.clinbiochem.2019.03.002_bb0330","article-title":"Fibroblast growth factor 23 and extracellular volume as markers of myocardial fibrosis and poor outcome in heart failure with preserved ejection fraction","volume":"39","author":"Roy","year":"2018","journal-title":"EHS"},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0335","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.008334","article-title":"Fibroblast growth factor-23 and heart failure with reduced versus preserved ejection fraction: MESA","volume":"7","author":"Almahmoud","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0340","doi-asserted-by":"crossref","first-page":"104","DOI":"10.15171\/jrip.2016.22","article-title":"A study on the association of serum fibroblast growth factor-23 with various indices of chronic kidney disease patients not yet on dialysis","volume":"5","author":"Yaghoubi","year":"2016","journal-title":"J. Renal Inj. Prev."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0345","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1053\/j.ajkd.2012.06.022","article-title":"Fibroblast growth factor 23, high-sensitivity cardiac troponin, and left ventricular hypertrophy in CKD","volume":"61","author":"Smith","year":"2013","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0350","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.peptides.2012.08.003","article-title":"C-terminal fgf23 is a strong predictor of survival in systolic heart failure","volume":"37","author":"Gruson","year":"2012","journal-title":"Peptides"},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0355","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/MNH.0b013e3282fd6e5b","article-title":"PHEX, FGF23, DMP1 and beyond","volume":"17","author":"Stroma","year":"2008","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0360","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.bone.2004.04.002","article-title":"FGF23 is processed by proprotein convertases but not by PHEX","volume":"35","author":"Benet-Pag\u00e8s","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0365","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1073\/pnas.0902006107","article-title":"Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation","volume":"107","author":"Goetza","year":"2005","journal-title":"PNAS"},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0370","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1210\/jc.2006-2865","article-title":"Determination of the elimination half-life of fibroblast growth Factor-23","volume":"92","author":"Khosravi","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0375","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1681\/ASN.2014121253","article-title":"Renal clearance of mineral metabolism biomarkers","volume":"27","author":"van Ballegooijen","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0380","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.cca.2011.02.009","article-title":"Instability of FGF23: implications for clinical studies","volume":"421","author":"Smith","year":"2011","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0385","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1515\/cclm-2013-0208","article-title":"Method-specific differences in plasma fibroblast growth factor 23 measurement using four commercial ELISAs","volume":"51","author":"Smith","year":"2013","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0390","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1373\/clinchem.2013.206649","article-title":"Pathophysiological implications of fibroblast growth Factor-23 and Klotho and their potential role as clinical biomarkers","volume":"60","author":"Donate-Correa","year":"2014","journal-title":"Clin. Chem."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0395","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1056\/NEJMoa020881","article-title":"Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia","volume":"348","author":"Jonsson","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0400","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1258\/acb.2009.009066","article-title":"Determination of fibroblast growth factor","volume":"46","author":"Heijboer","year":"2009","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0405","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1007\/s00198-016-3543-5","article-title":"Stability and degradation of fibroblast growth factor 23 (FGF23): the effect of time and temperature and assay type","volume":"27","author":"El-Maouche","year":"2016","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0410","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1210\/jc.2005-2105","article-title":"Sensitivity of FGF23 measurements in tumor induced osteomalacia","volume":"91","author":"Imel","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0415","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00774-011-0306-4","article-title":"Evaluation of a new automated chemiluminescence immunoassay for FGF23","volume":"30","author":"Shimizu","year":"2012","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0420","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.clinbiochem.2017.01.005","article-title":"Improving the translation of novel biomarkers to clinical practice: the story of cystatin C implementation in Canada. A professional practice column","volume":"50","author":"Ismail","year":"2017","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0425","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00223-017-0307-y","article-title":"Evaluation of a new fully automated assay for plasma iFGF23","volume":"101","author":"Souberbielle","year":"2017","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0430","doi-asserted-by":"crossref","first-page":"E352","DOI":"10.1210\/jc.2010-0589","article-title":"Circulating levels of soluble Klotho and FGF23 in X-linked hypophosphatemia: circadian variance, Effects of treatment, and relationship to parathyroid status","volume":"95","author":"Carpenter","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0435","first-page":"7","article-title":"Correlation of fibroblast growth factor 23 in chronic kidney disease patients with biochemical parameters and outcomes","volume":"4","author":"Yuvaraj","year":"2016","journal-title":"J. Parathyroid Dis."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0440","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1681\/ASN.2008121258","article-title":"Indirect regulation of PTH by estrogens may require FGF23","volume":"20","author":"Carrillo-Lopez","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0445","doi-asserted-by":"crossref","first-page":"E575","DOI":"10.1210\/jc.2011-2836","article-title":"Serum level of the Phosphaturic factor FGF23 is associated with abdominal aortic calcification in men: the STRAMBO study","volume":"97","author":"Schoppet","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0450","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4103\/1319-2442.198127","article-title":"Relation of fibroblast growth Factor-23 and cardiovascular calcification in end-stage kidney disease patients on regular hemodialysis","volume":"28","author":"El Baz","year":"2017","journal-title":"Saudi J. Kidney Dis. Transpl."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0455","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000346941","article-title":"Low body mass index and Dyslipidemia in Dialysis patients linked to elevated plasma fibroblast growth factor 23","volume":"37","author":"Montford","year":"2013","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0460","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/alcalc\/agx041","article-title":"Alpha Klotho and fibroblast growth Factor-23 among alcoholics","volume":"52","author":"Quintero-Platt","year":"2017","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0465","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.2215\/CJN.09250912","article-title":"Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD","volume":"8","author":"Isakova","year":"2013","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0470","doi-asserted-by":"crossref","first-page":"999","DOI":"10.2147\/TCRM.S142564","article-title":"Effect of additive calcium administration on FgF23 levels in patients with mild chronic kidney disease treated with calcitriol: a randomized, open-labeled clinical trial","volume":"13","author":"Han","year":"2017","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0475","first-page":"189","article-title":"Analytical issues with natriuretic peptides \u2013 has this been overly simplified?","volume":"27","author":"Semenov","year":"2016","journal-title":"eJIFCC"},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0480","article-title":"Natriuretic peptides and analytical barriers","author":"Vasile","year":"2016","journal-title":"Clin. Chem."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0485","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1373\/clinchem.2004.044594","article-title":"Quality specifications for B-type natriuretic peptide assays","volume":"51","author":"Apple","year":"2005","journal-title":"Clin. Chem."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0490","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1016\/j.jacc.2014.03.026","article-title":"Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease","volume":"63","author":"Udell","year":"2014","journal-title":"JACC"},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0495","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jchf.2015.05.012","article-title":"Association of Fibroblast Growth Factor-23 levels and angiotensin-converting enzyme inhibition in chronic systolic heart failure","volume":"3","author":"Wohlfahrt","year":"2015","journal-title":"JACC Heart Failure"},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0500","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s40265-018-0905-7","article-title":"Burosumab: first global approval","volume":"78","author":"Lamb","year":"2018","journal-title":"Drug"},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0505","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/jbmr.3544","article-title":"Burosumab: at long last, an effective treatment for FGF23-associated hypophosphatemia","volume":"33","author":"Collins","year":"2018","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0510","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1007\/s00253-014-6283-5","article-title":"Selection of a novel FGF23-binding peptide antagonizing the inhibitory effect of FGF23 on phosphate uptake","volume":"99","author":"Huang","year":"2015","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0515","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nrd.2015.9","article-title":"Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23","volume":"15","author":"Degirolamo","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.clinbiochem.2019.03.002_bb0520","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1042\/CS20150469","article-title":"The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment","volume":"130","author":"Volpe","year":"2016","journal-title":"Clin. Sci."}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000991201930013X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000991201930013X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T15:53:45Z","timestamp":1757865225000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000991201930013X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":104,"alternative-id":["S000991201930013X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2019.03.002","relation":{},"ISSN":["0009-9120"],"issn-type":[{"value":"0009-9120","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FGF23: Clinical usefulness and analytical evolution","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2019.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}